Cronos Group (TSE:CRON) Shares Down 0.3% – Time to Sell?

Cronos Group Inc. (TSE:CRON)’s stock price fell 0.3% during trading on Tuesday . The stock traded as low as C$3.92 and last traded at C$3.94. Approximately 197,661 shares traded hands during mid-day trading, an increase of 21% from the average session volume of 163,922 shares. The stock had previously closed at C$3.95.

Wall Street Analyst Weigh In

Separately, TD lifted their target price on shares of Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of C$4.75.

Cronos Group Trading Down 0.3%

The stock has a market capitalization of C$1.47 billion, a PE ratio of -188.00, a price-to-earnings-growth ratio of 0.12 and a beta of 1.13. The company has a current ratio of 21.87, a quick ratio of 24.01 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average price of C$3.90 and a 200-day moving average price of C$3.70.

Cronos Group (TSE:CRON) last issued its quarterly earnings results on Monday, May 11th. The company reported C$0.06 earnings per share for the quarter. The company had revenue of C$62.86 million for the quarter. Cronos Group had a negative net margin of 1.29% and a negative return on equity of 0.19%. As a group, equities analysts forecast that Cronos Group Inc. will post -0.26 EPS for the current fiscal year.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.